This review synthesizes current evidence on balancing the efficacy and toxicity of BCMA targeted therapies and details the mechanisms driving key immune related toxicities including cytokine release syndrome, immune effector cell associated neurotoxicity syndrome, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome and delayed neurotoxicities.
T-cell–based immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (bsAbs), have emerged as powerful treatment options for relapsed/refractory MM and will require investment in infrastructure, education, and interprofessional collaboration to ensure safe, equitable, and effec...
Michelly De Castro, DNP, ANP/GNP-BC, AOCNP, Karla V. Ow Msn Fnp-Bc· Journal of the Advanced Prac...· 0 citations
Simple Summary Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary immunotherapy that engineers a patient’s own immune T cells to specifically target and destroy malignant cells in hematological malignancies. This approach has transformed the treatment of relapsed acute lymphoblastic leukemia, lymphomas,...
Alaa A. A. Aljabali, Mohammad A. Obeid, A. Alqudah et al.· Cancers· 0 citations
The modularity and flexibility of the cCAR platform, along with the optimization of MA formats and clones, has the potential to enhance functional tuning of CAR T cell therapies, which may support improved efficacy and safety.
Chaitanya Tondepu, Andrew Wong, Clifford Wong et al.· Antibody Therapeutics· 0 citations
Next-generation ADCs may function not only as targeted cytotoxic agents but also as modulators of antitumor immunity in gastric cancer, and integrating tumor-antigen biology with immune-contextual features may enable more rational patient selection and therapeutic combinations.
Hong-Hua Su, Chun-Yin Yang, Jia-Yun Ge· Frontiers in Immunology· 0 citations
Abstract Despite innovative progress, cellular therapies have not produced durable, population-level survival gains in glioblastoma. Across 3 major modalities, engineered effectors such as chimeric antigen receptor T cell (CAR-T) and natural killer (NK) cells, immune-education platforms such as dendritic and whole-cell...
Rachael Mooney, E. A. Abd El-Fattah, G. Ngai et al.· Stem Cells Translational Med...· 0 citations
The evidence supports individualized treatment selection, biomarker-guided patient assessment, early recognition of toxicity, and multidisciplinary management in cancer immunotherapy, and considers emerging strategies for improving therapeutic precision.
M. Sri· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
